Uniqure N v (QURE) - News Archive

uniQure Makes a Bold Financial Move to Accelerate Gene Therapy InnovationsIn a significant financial move, uniQure N.V. a pioneering company at the forefront of gene therapy, has announced the pricing of its public offe...

The field of gene therapy continues to break new ground in the treatment of severe neurological disorders. We highlight two significant developments by uniQure N.V. a leader in gene therapy innovation, as they spearhead...

: uniQure N.V., a frontrunner in gene therapy, has made significant strides in the treatment of Fabry disease with the initiation of its Phase I/IIa clinical trial for AMT-191. This article delves into the details of th...

Reasons Behind UniQure N.V.’s Recent Stock Performance: A Month Overview In a month characterized by mixed market conditions, shares of UniQure N.V. have shown a divergence from broader trends. While the stock has faced...

uniQure, a major player in the field of gene therapy, recently announced the successful completion of the sale of its manufacturing facility to Genezen. This strategic move allows uniQure to consolidate its focus on pip...

In a world saturated with conformity and sameness, finding opportunities to experience something truly unique can be a breath of fresh air. Whether it s stepping back in time to relive the nostalgia of communist-era pos...

Huntington s disease is a rare, inherited neurodegenerative disorder that causes the progressive deterioration of nerve cells in the brain, leading to motor, cognitive, and psychiatric symptoms. Unfortunately, there is...

In a significant move aimed at streamlining its operations and reducing operating expenses, leading gene therapy company uniQure has recently announced the sale of its commercial manufacturing facility to Genezen. This...

Amid the relentless pursuit of finding a cure for neurological disorders, uniQure a leading gene therapy company reveals a significant development that may blaze trails in treating Huntington’s disease. The update revol...

In a recent development, uniQure, a leading gene therapy company, has announced the FDA clearance of their Investigational New Drug Application (IND) for AMT-191 gene therapy for Fabry Disease. This news is expected to...